• +1-646-491-9876
    • +91-20-67278686

    Search

    Impetigo Pipeline Review H1 2017

    Impetigo Pipeline Review H1 2017

    • Report Code ID: RW0001799276
    • Category Pharmaceuticals
    • No. of Pages 41
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Impetigo - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H1 2017, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.

    Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Impetigo - Overview
    Impetigo - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Impetigo - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Impetigo - Companies Involved in Therapeutics Development
    Destiny Pharma Ltd
    Foamix Pharmaceuticals Ltd
    Laboratories Ojer Pharma SL
    Lytix Biopharma AS
    Toyama Chemical Co Ltd
    Impetigo - Drug Profiles
    FMX-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LTX-109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mupirocin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ozenoxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XF-70 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Impetigo - Dormant Projects
    Impetigo - Discontinued Products
    Impetigo - Product Development Milestones
    Featured News & Press Releases
    May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)
    Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
    Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA
    Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
    Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer
    Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo
    Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study
    Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
    Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Impetigo, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Impetigo - Pipeline by Destiny Pharma Ltd, H1 2017
    Impetigo - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Impetigo - Pipeline by Laboratories Ojer Pharma SL, H1 2017
    Impetigo - Pipeline by Lytix Biopharma AS, H1 2017
    Impetigo - Pipeline by Toyama Chemical Co Ltd, H1 2017
    Impetigo - Dormant Projects, H1 2017
    Impetigo - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Impetigo, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Destiny Pharma Ltd
    Foamix Pharmaceuticals Ltd
    Laboratories Ojer Pharma SL
    Lytix Biopharma AS
    Toyama Chemical Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//impetigo-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments